For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 5,757,487 | |||
| General and administrative | 6,729,817 | |||
| Change in fair value of related party note | 154,832 | |||
| Operating loss | -12,642,136 | |||
| Interest income, net | 180,246 | |||
| Other income (expense), net | -32,370 | |||
| Net loss | -12,494,260 | |||
| Foreign currency translation loss | -87,340 | |||
| Comprehensive loss | -12,581,600 | |||
| Basic EPS | -2.93 | |||
| Diluted EPS | -2.93 | |||
| Basic Average Shares | 4,270,470 | |||
| Diluted Average Shares | 4,270,470 | |||
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)